Intra-abdominal desmoplastic small round-cell tumor (IADSRCT) is a rare mesenchymal tumor arising from the serosal surface of the abdominal peritoneum with an aggressive clinical course and poor survival ( Figure 1 ). It usually occurs in young males causing obstructive symptoms due to intra-abdominal or pelvic masses, with frequent peritoneal dissemination and metastases to liver, lungs, lymph nodes and BM. A pathognomonic chromosomal translocation, t(11;22)(p13;q12), is found in IADSRCT involving the fusion of the Wilms' tumor suppressor gene (WT1) on chromosome 11 to the Ewing sarcoma gene (EWS) on chromosome 22. 1 The chimeric gene product may exert a carcinogenic role through a dysregulation of a critical group of target genes. The presence of the specific fusion transcript is not only of diagnostic value but may also be of prognostic significance, when monitoring first-line chemotherapy reveals a persistence in peripheral blood or BM. 2 In IADSRCT, tumor regressions have been reported after intensive alkylatorbased chemotherapy, combined with surgery and radiotherapy; however, prolonged survival is rare, despite current therapeutic strategies.
We describe the favorable course of a 31-year-old patient with large tumor masses involving the left mesocolon and the pelvic region, showing long-term remission after multimodality treatment. After complete tumor resection including retroperitoneal lymph node dissection, in which 8 out of 25 lymph nodes showed tumor involvement, the patient received high-dose chemotherapy and autologous transplantation of 3-day ex vivo cultured CD34 þ -selected PBSCs. Detection of the specific EWS-exon 7/WT 1-exon 8 fusion transcript in tumor cells was performed by reverse transcription-PCR and was also measured on RNA isolated from a frozen sample of the unselected leukapheresis product. Despite the detection of tumor cells in the unselected PBSC product, the patient has remained in CR, ongoing for more than 10 years, thus being one of the few long-term survivors reported worldwide. As it has been shown that fusion proteins resulting from chromosomal translocations can be endogeneously processed and presented on the tumor cell surface by HLA class I molecules, thus being a potential target for T-cell-mediated immunity, 3 we evaluated whether the induction of tumor Ag-specific T cells directed against the fusion transcript was relevant for long-term response. It is interesting that in one IADSRCT with progressive disease, who received a matched allo-SCT after reduced-intensity conditioning, disappearance of the fusion transcript at the time of CYA tapering and acute GVHD development could be observed, 4 indicating an immune-mediated graft-vs-tumor effect. In our patient, the IFNg-enzyme-linked immunosorbent spot (ELISPOT) assay was performed after a 2-week restimulation of PBMCs with autologous DCs loaded with translocation-associated peptides. 3 As PBMCs from the time of initial diagnosis were not available, stimulation assays were performed with PBMCs collected 7.5 years after initial diagnosis. Long-term persistence of tumor Ag-specific CTLs in the absence of tumor or specific immunotherapy has already been reported. 5 However, in our patient no fusion peptide-specific T cells could be detected (Figure 2) . Nevertheless, the absence of detectable cells in the ELISPOT assay does not exclude an in vivo response, either because the Ag-specific T cells did not efficiently amplify under the in vitro stimulation conditions or because the frequency is below the detection threshold of 5 Â 10 À4 of CD4 þ or CD8 þ T cells. Furthermore, we performed immunohistochemical expression analysis with a large panel of MoAbs directed against tumor-associated antigens, such as antigens of the CancerTestis (C/T) gene family that are frequently expressed in some types of sarcoma 6 and neuroblastoma, possibly acting as immunological target antigens. 7 However, none of them were expressed in the patient's tumor specimen.
In our patient, using reverse transcription-PCR, the unselected leukapheresis product revealed contaminating tumor cells. This is in accordance with earlier reports that, in IADSRCT, the characteristic t(11;22) translocation is frequently present in peripheral blood and BM cells. 2 After CD34 þ selection, tumor cell contamination might have been markedly reduced, although in Ewing sarcoma (ES) patients, the role of CD34 þ selection has been controversially discussed, as the CD34 expression can be occasionally detected in ES cells, bearing the potential risk that tumor cells are even enriched after CD34 þ selection. Not having backup aliquots of CD34 þ -selected PBSCs of our patient, we could not analyze tumor cell contamination of CD34 þ -PBSCs, but as the CD34 Ag was not expressed in the IADSRCT specimen itself, this makes tumor cell enrichment after CD34 þ selection highly unlikely. We suggest that the intensive chemotherapy initiated early after complete tumor resection, followed by transplantation of CD34 þ -selected, ex vivo cultured PBSCs, most likely free of residual tumor cells because of the purging strategy, 8 contributed to this favorable course. Gene marking analysis has helped to clarify the impact of tumor cell contamination of stem cell products on clinical outcome. 9 Although randomized clinical trials are required to determine the benefit of in vitro purging on disease progression and OS, these are difficult to perform in rare disease entities and have shown a substantial clinical benefit for some cancer types with limited patient numbers.
Future treatment approaches may involve the development of novel immunotherapeutic strategies, specifically targeting tumor-restricted surface antigens or cellular regulatory mechanisms of IADSRCT. 
